Brief: Transgene Presents The Detailed Results From Phase 1b/2 Trial Combining TG4001 with avelumab (BAVENCIO®)

Transgene SA

09/11/2020 16:51

Nov 9 (Reuters) - TRANSGENE SA  TRNG.PA :
    * TRANSGENE PRESENTS E-POSTER OUTLINING DETAILED RESULTS
FROM THE
PHASE 1B/2 TRIAL OF TG4001 IN COMBINATION WITH AVELUMAB IN
ADVANCED HPV-POSITIVE CANCERS AT SITC 2020
    * COMBINATION OF TG4001 AND AVELUMAB DEMONSTRATED A
CLINICALLY
RELEVANT ANTI-TUMOR ACTIVITY WITH AN OVERALL RESPONSE RATE (ORR)
OF 23.5%
    * PRESENCE OF LIVER METASTASES HAD A NOTABLE IMPACT ON
OUTCOMES:
IN PATIENTS WITHOUT LIVER METASTASES, AN ORR OF 34.8% AND A
MEDIAN PROGRESSION-FREE SURVIVAL (PFS) OF 5.6 MONTHS WERE
ACHIEVED
    * TREATMENT ASSOCIATED WITH CHANGES IN TUMOR
MICROENVIRONMENT
CHARACTERIZED BY A SIGNIFICANT AND SUSTAINABLE IMMUNE RESPONSE
AND ACTIVITY AGAINST TUMOR

Source text for Eikon:  ID:nBw74tQ2Na 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))